Abstract | INTRODUCTION: METHODS: This was a double-blind incomplete crossover trial in which 233 patients with moderate or severe COPD were randomized to receive four out of eight free-dose combinations of olodaterol (5 or 10 µg) and tiotropium (1.25, 2.5, or 5 µg) or placebo for 4 weeks each. Primary end point was trough forced expiratory volume in 1 s (FEV1) change from baseline (response) after 4 weeks. RESULTS: Addition of tiotropium 1.25, 2.5, and 5 µg to olodaterol 5 µg increased mean trough FEV1 response by 0.054, 0.065, and 0.084 L, respectively; addition of tiotropium 1.25, 2.5, and 5 µg to olodaterol 10 µg increased mean trough FEV1 response by 0.051, 0.083, and 0.080 L, respectively. All treatments were well tolerated and incidence of adverse events was similar with all treatments. CONCLUSIONS: FUNDING: Boehringer Ingelheim. TRIAL REGISTRATION: ClinicalTrials.gov number, NCT01040403.
|
Authors | René Aalbers, M Reza Maleki-Yazdi, Alan Hamilton, Stella Waitere-Wijker, Yihua Zhao, Valeria C Amatto, Olaf Schmidt, Leif Bjermer |
Journal | Advances in therapy
(Adv Ther)
Vol. 32
Issue 9
Pg. 809-22
(Sep 2015)
ISSN: 1865-8652 [Electronic] United States |
PMID | 26404912
(Publication Type: Clinical Trial, Phase II, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Benzoxazines
- Bronchodilator Agents
- olodaterol
- Tiotropium Bromide
|
Topics |
- Aged
- Benzoxazines
(administration & dosage)
- Bronchodilator Agents
(administration & dosage)
- Cross-Over Studies
- Double-Blind Method
- Female
- Forced Expiratory Volume
- Humans
- Male
- Middle Aged
- Nebulizers and Vaporizers
- Pulmonary Disease, Chronic Obstructive
(drug therapy, physiopathology)
- Tiotropium Bromide
(administration & dosage)
- Treatment Outcome
|